IGM Biosciences shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $9 to $21.
Portfolio Pulse from Benzinga Newsdesk
IGM Biosciences' stock price is on the rise following an upgrade by RBC Capital from Sector Perform to Outperform, along with an increase in the price target from $9 to $21.
February 09, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IGM Biosciences sees a positive shift in stock valuation after RBC Capital's upgrade to Outperform and a significant raise in its price target.
The upgrade by RBC Capital from Sector Perform to Outperform, coupled with a more than doubling of the price target from $9 to $21, signals strong confidence in IGM Biosciences' future performance. This analyst action can significantly influence investor sentiment and stock price in the short term, as upgrades and revised price targets are closely watched indicators of a stock's potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100